Andrew J. Webb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Andrew J. Webb has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Brooke Barlow
Department of Pharmacy Services University of Kentucky HealthCare Lexington Kentucky USA
3 shared publications - Cassie A. Barton
Department of Pharmacy, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
3 shared publications - Eric S. Rosenthal
Harvard Medical School
3 shared publications Riley Johnson
Department of Pharmacy, Massachusetts General Hospital, Boston, USA
3 shared publicationsSahar F. Zafar
Department of Neurology Mass General Brigham/Harvard Medical School Boston Massachusetts USA
3 shared publicationsAshley Barlow
Department of Pharmacy Services MD Anderson Cancer Center Houston Texas USA
2 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Elsevier in Intelligence-Based Medicine
- Vol. 16
CICADAS: A simulation-based framework for randomized trial emulation in critical-care seizure treatment
- 16 September 2026
- Published by Elsevier in Intelligence-Based Medicine
- Vol. 16
Open AccessCICADAS: A simulation-based framework for randomized trial emulation in critical-care seizure treatment
- 15 July 2026
- Published by Springer Nature in Intensive Care Medicine
- Vol. 52 (10) , 2144-2159
Antiseizure medication dosing and monitoring in the intensive care unit: a practical narrative review
Antiseizure medications (ASMs) are commonly used in the intensive care unit (ICU) and often exhibit pharmacokinetics that differ substantially from those in healthy volunteers or in the outpatient setting. Organ dysfunction, polypharmacy, exogenous devices, and greater severity of illness all influence ASM pharmacokinetics, dosing decisions, and monitoring parameters. It is essential for critical care clinicians to familiarize themselves with the pharmacokinetics, dosing considerations, effects of exogenous devices, and therapeutic drug monitoring (TDM)-all covered in this narrative review-to incorporate in their approach to ASMs in the critical care setting. We identified relevant literature from MEDLINE from inception to March 2026 related to ASMs in the ICU. Data on pharmacokinetics, dosing in the ICU, the effect of renal replacement therapy, extracorporeal membrane oxygenation (ECMO), and plasmapheresis (PLEX) on ASM exposure, and the role of TDM in the ICU were collected and summarized. Considerations for 15 ASMs (brivaracetam, cannabidiol, carbamazepine, cenobamate, clobazam, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, phenobarbital, phenytoin, topiramate, valproate, and zonisamide) were included in the review. Dosing considerations for TDM, including indications and target reference ranges, and specific settings such as organ dysfunction, illness severity, renal replacement therapy, ECMO, and PLEX are discussed. The use of ASMs in the ICU require a distinct approach from outpatient settings. Severity of illness, organ dysfunction and replacement devices, and frequent drug-drug interactions warrant tailored agent selection, dosing, and monitoring.
- 15 July 2026
- Published by Springer Nature in Intensive Care Medicine
- Vol. 52 (10) , 2144-2159
Antiseizure medication dosing and monitoring in the intensive care unit: a practical narrative review
Antiseizure medications (ASMs) are commonly used in the intensive care unit (ICU) and often exhibit pharmacokinetics that differ substantially from those in healthy volunteers or in the outpatient setting. Organ dysfunction, polypharmacy, exogenous devices, and greater severity of illness all influence ASM pharmacokinetics, dosing decisions, and monitoring parameters. It is essential for critical care clinicians to familiarize themselves with the pharmacokinetics, dosing considerations, effects of exogenous devices, and therapeutic drug monitoring (TDM)-all covered in this narrative review-to incorporate in their approach to ASMs in the critical care setting. We identified relevant literature from MEDLINE from inception to March 2026 related to ASMs in the ICU. Data on pharmacokinetics, dosing in the ICU, the effect of renal replacement therapy, extracorporeal membrane oxygenation (ECMO), and plasmapheresis (PLEX) on ASM exposure, and the role of TDM in the ICU were collected and summarized. Considerations for 15 ASMs (brivaracetam, cannabidiol, carbamazepine, cenobamate, clobazam, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, phenobarbital, phenytoin, topiramate, valproate, and zonisamide) were included in the review. Dosing considerations for TDM, including indications and target reference ranges, and specific settings such as organ dysfunction, illness severity, renal replacement therapy, ECMO, and PLEX are discussed. The use of ASMs in the ICU require a distinct approach from outpatient settings. Severity of illness, organ dysfunction and replacement devices, and frequent drug-drug interactions warrant tailored agent selection, dosing, and monitoring.
- 10 July 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Speed and Safety of IV Push Versus IV Piggyback Valproate Loading Doses: A Retrospective Cohort Study
Background: Delays in intravenous antiseizure medication (ASM) administration may worsen seizure outcomes. Intravenous push (IVP) administration reduces administration time for several ASMs, but evidence for IVP valproate loading is limited. Objective: To compare time from pharmacist verification to documented administration for IVP versus intravenous piggyback (IVPB) valproate loading doses and compare adverse event frequencies. Methods: This single-center retrospective study included adults from October 2023 to May 2025 who received an IV valproate loading dose (≥15 mg/kg). On August 15, 2024, institutional practice changed from IVPB valproate more than 60 minutes to undiluted IVP valproate at 500 mg/min. The primary outcome was time from pharmacist verification to loading dose administration. Secondary outcomes included order-to-administration time, adverse events, intensive care unit (ICU) admission, length of stay, and mortality. Results: One hundred thirty-one patients met the inclusion criteria (IVP, n = 60; IVPB, n = 71). Median (interquartile range [IQR]) age was 63 years (44-71), and 85 (65%) patients were male. Valproate indications were witnessed seizure in 92 (70.2%), suspected seizure in 29 (22.1%), and agitation/psychiatric in 10 (7.6%). Sixty-four (48.8%) patients received loading doses for status epilepticus. The median (IQR) loading dose was 28 (20-34.5) mg/kg. Median time to administration was 36 (95% CI, 22-52) minutes shorter with IVP than with IVPB (median [IQR], 28 [13-48] vs 63 [50-84] minutes; P < 0.001). Cardiovascular events occurred in 38.3% and 27.8% of IVP and IVPB patients ( P = 0.27); sedation in 3.3% and 0% ( P = 0.20); and valproate-associated adverse events in 6.7% and 1.4% ( P = 0.18). No phlebitis or infiltration occurred. Conclusion and Relevance: Intravenous push valproate loading reduced time to administration without an observed increase in adverse events.
- 10 July 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Speed and Safety of IV Push Versus IV Piggyback Valproate Loading Doses: A Retrospective Cohort Study
Background: Delays in intravenous antiseizure medication (ASM) administration may worsen seizure outcomes. Intravenous push (IVP) administration reduces administration time for several ASMs, but evidence for IVP valproate loading is limited. Objective: To compare time from pharmacist verification to documented administration for IVP versus intravenous piggyback (IVPB) valproate loading doses and compare adverse event frequencies. Methods: This single-center retrospective study included adults from October 2023 to May 2025 who received an IV valproate loading dose (≥15 mg/kg). On August 15, 2024, institutional practice changed from IVPB valproate more than 60 minutes to undiluted IVP valproate at 500 mg/min. The primary outcome was time from pharmacist verification to loading dose administration. Secondary outcomes included order-to-administration time, adverse events, intensive care unit (ICU) admission, length of stay, and mortality. Results: One hundred thirty-one patients met the inclusion criteria (IVP, n = 60; IVPB, n = 71). Median (interquartile range [IQR]) age was 63 years (44-71), and 85 (65%) patients were male. Valproate indications were witnessed seizure in 92 (70.2%), suspected seizure in 29 (22.1%), and agitation/psychiatric in 10 (7.6%). Sixty-four (48.8%) patients received loading doses for status epilepticus. The median (IQR) loading dose was 28 (20-34.5) mg/kg. Median time to administration was 36 (95% CI, 22-52) minutes shorter with IVP than with IVPB (median [IQR], 28 [13-48] vs 63 [50-84] minutes; P < 0.001). Cardiovascular events occurred in 38.3% and 27.8% of IVP and IVPB patients ( P = 0.27); sedation in 3.3% and 0% ( P = 0.20); and valproate-associated adverse events in 6.7% and 1.4% ( P = 0.18). No phlebitis or infiltration occurred. Conclusion and Relevance: Intravenous push valproate loading reduced time to administration without an observed increase in adverse events.
- 28 May 2026
- Published by SAGE Publications in Hospital Pharmacy
Comparison of Cystatin C-Based and Serum Creatinine-Based Renal Function Estimates Against Timed Urine Collection in Critically Ill Patients
Background: Creatinine-based estimation equations for renal function, especially the Cockcroft-Gault creatinine clearance (CG-CrCL) equation, may be inaccurate in critically ill patients. We sought to determine if a cystatin C (CysC)-based (CKD-EPI CysC-serum creatinine (SCr) estimated glomerular filtration rate [eGFRcr-cys]) calculation better estimated renal clearance compared to CG-CrCL against measured creatinine clearance (mCrCL) from timed urine creatinine collection in adult critically ill patients. Materials and methods: This was a single-center retrospective cohort study of adult patients admitted to an intensive care unit (ICU) between July 1, 2022, and July 31, 2023, who had concurrent creatinine and cystatin C measured within 24 hours of a timed urine creatinine collection. The primary outcome was the mean difference in bias between eGFRcr-cys and C-G CrCL compared to timed urine creatinine collection. eGFR was adjusted for body surface area (BSA) and reported as mL/min. Results: Forty-five patients were included in this study. The mean bias between C-G CrCL and mCrCL was 23.8 mL/min (95% CI −40.3 to 87.8 mL/min) and 3.3 mL/min (95% CI −43.3 to 49.9 mL/min) between eGFRcr-cys and mCrCL. The mean difference between the biases was 20.5 mL/min ( P = .001). Conclusions: In critically ill patients, eGFRcr-cys was subject to less bias compared to C-G CrCL. Future research is needed to better understand the clinical implications of using eGFRcr-cys over C-G CrCL, particularly for medication-related decision making in critically ill patients.
- 28 May 2026
- Published by SAGE Publications in Hospital Pharmacy
Comparison of Cystatin C-Based and Serum Creatinine-Based Renal Function Estimates Against Timed Urine Collection in Critically Ill Patients
Background: Creatinine-based estimation equations for renal function, especially the Cockcroft-Gault creatinine clearance (CG-CrCL) equation, may be inaccurate in critically ill patients. We sought to determine if a cystatin C (CysC)-based (CKD-EPI CysC-serum creatinine (SCr) estimated glomerular filtration rate [eGFRcr-cys]) calculation better estimated renal clearance compared to CG-CrCL against measured creatinine clearance (mCrCL) from timed urine creatinine collection in adult critically ill patients. Materials and methods: This was a single-center retrospective cohort study of adult patients admitted to an intensive care unit (ICU) between July 1, 2022, and July 31, 2023, who had concurrent creatinine and cystatin C measured within 24 hours of a timed urine creatinine collection. The primary outcome was the mean difference in bias between eGFRcr-cys and C-G CrCL compared to timed urine creatinine collection. eGFR was adjusted for body surface area (BSA) and reported as mL/min. Results: Forty-five patients were included in this study. The mean bias between C-G CrCL and mCrCL was 23.8 mL/min (95% CI −40.3 to 87.8 mL/min) and 3.3 mL/min (95% CI −43.3 to 49.9 mL/min) between eGFRcr-cys and mCrCL. The mean difference between the biases was 20.5 mL/min ( P = .001). Conclusions: In critically ill patients, eGFRcr-cys was subject to less bias compared to C-G CrCL. Future research is needed to better understand the clinical implications of using eGFRcr-cys over C-G CrCL, particularly for medication-related decision making in critically ill patients.
- Open Access
- 1 January 2026
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 32
Expert Opinion on Implementing Oral Anticoagulation Reversal Protocols in US Hospitals
Oral anticoagulants (OACs), including vitamin K antagonists and direct-acting OACs, are commonly used for the prevention and treatment of thrombosis. OAC-treated patients may require urgent anticoagulation reversal in circumstances of life-threatening bleeding or emergent surgery. Despite the availability of Food and Drug Administration-approved OAC reversal agents, published treatment guidelines, and institutional protocols, use of OAC reversal products and dosing vary considerably and off-label use is common. We review key factors influencing current clinical practice and examine barriers to the successful implementation of anticoagulation protocols, including discrepancies in the definition of major bleeding, dosing considerations, variability in laboratory testing practices, inconsistent study endpoints, formulary considerations, and the use of OAC reversal agents in special populations. We provide our expert opinion on best practices for oral anticoagulant reversal and an anticoagulation reversal protocol that could be implemented by healthcare institutions to standardize and optimize clinical practice.
- 1 January 2026
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 32
Open AccessExpert Opinion on Implementing Oral Anticoagulation Reversal Protocols in US Hospitals
Oral anticoagulants (OACs), including vitamin K antagonists and direct-acting OACs, are commonly used for the prevention and treatment of thrombosis. OAC-treated patients may require urgent anticoagulation reversal in circumstances of life-threatening bleeding or emergent surgery. Despite the availability of Food and Drug Administration-approved OAC reversal agents, published treatment guidelines, and institutional protocols, use of OAC reversal products and dosing vary considerably and off-label use is common. We review key factors influencing current clinical practice and examine barriers to the successful implementation of anticoagulation protocols, including discrepancies in the definition of major bleeding, dosing considerations, variability in laboratory testing practices, inconsistent study endpoints, formulary considerations, and the use of OAC reversal agents in special populations. We provide our expert opinion on best practices for oral anticoagulant reversal and an anticoagulation reversal protocol that could be implemented by healthcare institutions to standardize and optimize clinical practice.
- 17 November 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (12) , 831-839
External Validation of the Fraser Equation for Estimation of Free Valproate Concentrations in Critically Ill Adults
Background: Critically ill patients may be overexposed to valproate because altered protein binding leads to a disproportionate free valproate fraction. The Fraser equation was derived and internally validated to estimate critically ill patients' free valproate concentrations, but it requires external validation. Methods: Adult intensive care unit (ICU) patients at two academic centers with concurrently measured free and total valproate concentrations were included. Free valproate concentrations were estimated using the Fraser equation which includes total valproate, albumin and BUN concentration, and whether the patient received propofol or aspirin. The primary outcome was Fraser equation performance, assessed using Bland–Altman methods. Comparative performance against estimates from the Doré equation (an alternative predictive equation), therapeutic concordance using a target free valproate range of 5–15 mg/L, and equation improvements were explored. Results: Overall, 315 patients and 556 free‐total valproate concentration pairs were included. The mean (±SD) age was 58 (±17) years and 90 (29%) patients were on valproate prior to hospital admission. The Fraser equation estimated free valproate concentrations were correlated with measured concentrations ( r = 0.728) with a negative bias (mean bias −2.77 mg/L, 95% LOA –18.9, 13.4). The Fraser equation increasingly underestimated measured concentrations as measured concentrations increased. 71% of Fraser equation estimates were therapeutically concordant (e.g., estimate and measured both within reference range) compared to 61.9% of Doré estimates ( p = 0.001). Fraser equation modifications led to minor performance improvements but did not overcome worsening underestimation with higher measured free valproate concentrations. Conclusion: The Fraser equation was moderately accurate and corresponded with an appropriate interpretation for 71% of free valproate concentrations. Worse underestimation with higher measured free valproate concentrations suggests direct measurement of free valproate concentrations is warranted. While the Fraser equation could complement therapeutic decision making at centers where direct free valproate measurements are unavailable or slow to return, its accuracy is currently insufficient to replace direct measurement.
- 17 November 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (12) , 831-839
External Validation of the Fraser Equation for Estimation of Free Valproate Concentrations in Critically Ill Adults
Background: Critically ill patients may be overexposed to valproate because altered protein binding leads to a disproportionate free valproate fraction. The Fraser equation was derived and internally validated to estimate critically ill patients' free valproate concentrations, but it requires external validation. Methods: Adult intensive care unit (ICU) patients at two academic centers with concurrently measured free and total valproate concentrations were included. Free valproate concentrations were estimated using the Fraser equation which includes total valproate, albumin and BUN concentration, and whether the patient received propofol or aspirin. The primary outcome was Fraser equation performance, assessed using Bland–Altman methods. Comparative performance against estimates from the Doré equation (an alternative predictive equation), therapeutic concordance using a target free valproate range of 5–15 mg/L, and equation improvements were explored. Results: Overall, 315 patients and 556 free‐total valproate concentration pairs were included. The mean (±SD) age was 58 (±17) years and 90 (29%) patients were on valproate prior to hospital admission. The Fraser equation estimated free valproate concentrations were correlated with measured concentrations ( r = 0.728) with a negative bias (mean bias −2.77 mg/L, 95% LOA –18.9, 13.4). The Fraser equation increasingly underestimated measured concentrations as measured concentrations increased. 71% of Fraser equation estimates were therapeutically concordant (e.g., estimate and measured both within reference range) compared to 61.9% of Doré estimates ( p = 0.001). Fraser equation modifications led to minor performance improvements but did not overcome worsening underestimation with higher measured free valproate concentrations. Conclusion: The Fraser equation was moderately accurate and corresponded with an appropriate interpretation for 71% of free valproate concentrations. Worse underestimation with higher measured free valproate concentrations suggests direct measurement of free valproate concentrations is warranted. While the Fraser equation could complement therapeutic decision making at centers where direct free valproate measurements are unavailable or slow to return, its accuracy is currently insufficient to replace direct measurement.
- 6 October 2025
- Published by Taylor & Francis in The Journal of Spinal Cord Medicine
- Vol. 49 (4) , 753-761
Vasopressin-induced hyponatremia during mean arterial pressure augmentation in acute spinal cord injury: A multicenter retrospective cohort study
MAP augmentation is a guideline-recommended intervention in acute spinal cord injury (SCI), and vasopressin can be used to achieve mean arterial pressure (MAP) goals. Vasopressin could contribute to hyponatremia in SCI, but this relationship is poorly described. This was a multicenter, retrospective, observational cohort of patients with acute SCI who received vasopressin only for MAP augmentation and developed hyponatremia. Patients were excluded if vasopressin was used for e.g. shock states). The primary outcome was the probability hyponatremia was caused by vasopressin, determined using the Naranjo Adverse Drug Reaction Probability Scale. Twenty patients with SCI received vasopressin for MAP augmentation and 17 (85%) developed hyponatremia. Seventy percent of patients received an American Spinal Injury Association Impairment Scale (AIS) classification at admission: AIS A (42%), AIS B (50%), and AIS C (8%). MAP augmentation (mean goal of 87 (±7) mm Hg) was maintained for 5 (±2) days. The median Naranjo score was 7 (range 4-9), constituting a "probable" association of vasopressin with hyponatremia. Hyponatremia (Na <135 mEq/L) developed within 30 (±20) hours of vasopressin initiation, with a nadir at 129 (±4) mEq/L. Sodium declined by 8 mEq/L on average for every 24 h of vasopressin exposure. Hyponatremia resolved 12 (±9) hours after vasopressin discontinuation. Five patients were rechallenged with vasopressin and 4 (80%) re-developed hyponatremia. Vasopressin used for MAP augmentation was associated with hyponatremia in patients with SCI who received it strictly for MAP augmentation and resolved after discontinuation. Providers should exercise caution when selecting vasopressin for MAP augmentation in acute SCI.
- 6 October 2025
- Published by Taylor & Francis in The Journal of Spinal Cord Medicine
- Vol. 49 (4) , 753-761
Vasopressin-induced hyponatremia during mean arterial pressure augmentation in acute spinal cord injury: A multicenter retrospective cohort study
MAP augmentation is a guideline-recommended intervention in acute spinal cord injury (SCI), and vasopressin can be used to achieve mean arterial pressure (MAP) goals. Vasopressin could contribute to hyponatremia in SCI, but this relationship is poorly described. This was a multicenter, retrospective, observational cohort of patients with acute SCI who received vasopressin only for MAP augmentation and developed hyponatremia. Patients were excluded if vasopressin was used for e.g. shock states). The primary outcome was the probability hyponatremia was caused by vasopressin, determined using the Naranjo Adverse Drug Reaction Probability Scale. Twenty patients with SCI received vasopressin for MAP augmentation and 17 (85%) developed hyponatremia. Seventy percent of patients received an American Spinal Injury Association Impairment Scale (AIS) classification at admission: AIS A (42%), AIS B (50%), and AIS C (8%). MAP augmentation (mean goal of 87 (±7) mm Hg) was maintained for 5 (±2) days. The median Naranjo score was 7 (range 4-9), constituting a "probable" association of vasopressin with hyponatremia. Hyponatremia (Na <135 mEq/L) developed within 30 (±20) hours of vasopressin initiation, with a nadir at 129 (±4) mEq/L. Sodium declined by 8 mEq/L on average for every 24 h of vasopressin exposure. Hyponatremia resolved 12 (±9) hours after vasopressin discontinuation. Five patients were rechallenged with vasopressin and 4 (80%) re-developed hyponatremia. Vasopressin used for MAP augmentation was associated with hyponatremia in patients with SCI who received it strictly for MAP augmentation and resolved after discontinuation. Providers should exercise caution when selecting vasopressin for MAP augmentation in acute SCI.
- 11 September 2025
- Published by Wiley in Academic Emergency Medicine
- Vol. 33 (1)
Hemodynamics Following Dexmedetomidine Loading Dose From Infusion
- 11 September 2025
- Published by Wiley in Academic Emergency Medicine
- Vol. 33 (1)
Hemodynamics Following Dexmedetomidine Loading Dose From Infusion
- 28 August 2025
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 55 (4) , 531-534
Worth the Weight? Problems with FDA-Labeled Tenecteplase Dosing for Acute Ischemic Stroke
- 28 August 2025
- Published by S. Karger AG in Cerebrovascular Diseases
- Vol. 55 (4) , 531-534
Worth the Weight? Problems with FDA-Labeled Tenecteplase Dosing for Acute Ischemic Stroke
- 12 June 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (5) , 1372-1377
Multicenter evaluation of the safety and efficacy of varying doses of cangrelor used in acute cerebrovascular stenting in patients with acute ischemic stroke
Background Acute ischemic stroke often necessitates neuroendovascular interventions such as thrombectomy and, occasionally, stenting for large vessel occlusions or intracranial atherosclerotic disease. Effective antiplatelet therapy is essential during stenting to mitigate thrombosis risks, but consensus on optimal cangrelor dosing remains elusive. This study evaluates the safety and efficacy of various cangrelor doses used in acute cerebrovascular stenting. Methods A multicenter, retrospective cohort study was conducted across 11 comprehensive stroke centers. Patients aged 18–85 with ischemic stroke who underwent emergent cerebrovascular stenting with cangrelor were included. Patients were categorized into low-dose cangrelor (Results A total of 230 patients were included in the analysis (LDC: 68; HDC: 162). Baseline characteristics were similar between groups. Thrombotic outcomes, including intraprocedural thrombosis (13% LDC vs 6% HDC; P=0.078) and thrombosis within 48 hours of the procedure (9% LDC vs 4% HDC; P=0.093), showed no statistical differences. Similarly, intraprocedural bleeding (6% LDC vs 5% HDC; P=0.753) and intracranial hemorrhage within 48 hours of the procedure (19% LDC vs 25% HDC; P=0.360) were not statistically different. Conclusion Different cangrelor dosing regimens demonstrated no significant differences in thrombotic or bleeding complications during acute neuroendovascular stenting for ischemic stroke. Larger, prospective studies are warranted to refine optimal dosing strategies for cangrelor in this population.
- 12 June 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (5) , 1372-1377
Multicenter evaluation of the safety and efficacy of varying doses of cangrelor used in acute cerebrovascular stenting in patients with acute ischemic stroke
Background Acute ischemic stroke often necessitates neuroendovascular interventions such as thrombectomy and, occasionally, stenting for large vessel occlusions or intracranial atherosclerotic disease. Effective antiplatelet therapy is essential during stenting to mitigate thrombosis risks, but consensus on optimal cangrelor dosing remains elusive. This study evaluates the safety and efficacy of various cangrelor doses used in acute cerebrovascular stenting. Methods A multicenter, retrospective cohort study was conducted across 11 comprehensive stroke centers. Patients aged 18–85 with ischemic stroke who underwent emergent cerebrovascular stenting with cangrelor were included. Patients were categorized into low-dose cangrelor (Results A total of 230 patients were included in the analysis (LDC: 68; HDC: 162). Baseline characteristics were similar between groups. Thrombotic outcomes, including intraprocedural thrombosis (13% LDC vs 6% HDC; P=0.078) and thrombosis within 48 hours of the procedure (9% LDC vs 4% HDC; P=0.093), showed no statistical differences. Similarly, intraprocedural bleeding (6% LDC vs 5% HDC; P=0.753) and intracranial hemorrhage within 48 hours of the procedure (19% LDC vs 25% HDC; P=0.360) were not statistically different. Conclusion Different cangrelor dosing regimens demonstrated no significant differences in thrombotic or bleeding complications during acute neuroendovascular stenting for ischemic stroke. Larger, prospective studies are warranted to refine optimal dosing strategies for cangrelor in this population.